Abstract
In February 2004, pemetrexed disodium (Alimta; Eli Lilly), an anticancer drug that targets folate-dependent reactions that are essential for cell proliferation, became the first drug to be approved by the FDA for the treatment of the rare cancer malignant pleural mesothelioma. Its accelerated approval for the second-line treatment of non-small-cell lung cancer, which will considerably increase its market potential, followed in August 2004.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Takimoto, C. H. New antifolates: pharmacology and clinical applications. The Oncologist 1, 68–81 (1996).
Hanauske, A. -R. et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. The Oncologist 6, 363–373 (2001).
Taylor, E. C. et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6,N-[4-[2-(2-amino-3,4 dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J. Med. Chem. 35, 4450–4454 (1992).
Shih, C. et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57, 1116–1123 (1997).
FDA drug approvals list [online], <http://www.fda.gov/cder/foi/label/2004/021677lbl.pdf> (2004).
Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636–2644 (2003).
Hanna, N. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589–1597 (2004).
Etiology and epidemiology of MPM [online], <http://www.rsna.org/REG/publications/rg/afip/privateM/index.htm#topAnchor>
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muhsin, M., Gricks, C. & Kirkpatrick, P. Pemetrexed disodium. Nat Rev Drug Discov 3, 825–826 (2004). https://doi.org/10.1038/nrd1528
Issue Date:
DOI: https://doi.org/10.1038/nrd1528
This article is cited by
-
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902
Cancer Chemotherapy and Pharmacology (2014)
-
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
Cancer Chemotherapy and Pharmacology (2013)
-
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902
Cancer Chemotherapy and Pharmacology (2012)
-
5,6-Dihydro-2H-pyranones and 5,6-dihydro-2H-pyridones and their derivatives modulate in vitro human T lymphocyte function
Molecular and Cellular Biochemistry (2012)
-
Synthesis and cytotoxicity of phenyl-vinyl derivatives of 4,6,6-trimethyl-2-oxo-1,2,5,6-tetrahydropyridine-3-carbonitrile
Chemistry of Heterocyclic Compounds (2009)
